Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair (REPAIR)

Real-Life Use of Transabdominal Restorelle® Meshes in Apical Prolapse Repair: an Observational Post-Market Clinical Study

The purpose of this study is to prospectively follow patients after a sacrocolpopexy with Restorelle® mesh for apical prolapse repair as part of routine care. It will help to describe the safety profile and to confirm the clinical benefits of Restorelle mesh for at least 5 to 8 years post-surgery.

Study Overview

• Status: Terminated
• Conditions: Genital Prolapse
• Intervention / Treatment: Device: Restorelle Polypropylene Mesh

Detailed Description

This study is a non-interventional, multicenter and post market clinical follow-up in adult women with apical prolapse under normal conditions of use (after a sacrocolpopexy with Restorelle mesh for apical prolapse repair as part of routine care). The patient will be followed for 1 year (or less) by the investigator as per local usual practice. At the same time, the patient will be followed via PRO (Patient Reported Outcomes) over a period of 5 to 8 years.

• Study Type: Observational
• Enrollment (Actual): 39

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • CHU Pellegrin
  • La Rochelle, France, 17019
    • CH La Rochelle
  • Le Puy-en-Velay, France, 43000
    • Clinique Bon Secours
  • Paris, France, 75014
    • Institut Mutualiste Montsouris
  • Saintes, France, 17108
    • CH de Saintonge
  • Choisir Une Région
    • Avranches, Choisir Une Région, France, 50300
      • Polyclinique de la Baie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Adult female patients presenting with apical pelvic organ prolapse which is clinically indicated for a surgical treatment with Restorelle mesh

Description

Inclusion Criteria:

• Female patient of at least 18 years old
• Patient presenting apical pelvic organ prolapse and being eligible to surgical treatment
• Surgeon having decided to treat the patient with a Restorelle mesh as per its CE mark indication and IFU, before patient inclusion
• Patient having received appropriate information and counselling before mesh implantation
• Patient has been provided written informed consent

Exclusion Criteria:

• Patient currently pregnant or breastfeeding
• Patient being deprived of liberty by a judicial or administrative decision, or who is under a measure of legal protection

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The incidence rate of a surgical reintervention related to Restorelle mesh use over at least the 5 first years of post-index procedure follow-up	up to 5 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence rate of surgical reintervention related to Restorelle mesh use in patients		through study completion, at least 5 and up to 8 years
Number of patients who have only had surgical reintervention not related to Restorelle mesh use		through study completion, at least 5 and up to 8 years
Percentage of patients who have only had surgical reintervention not related to Restorelle mesh use		through study completion, at least 5 and up to 8 years
Number of patients who have had more than 1 surgical reintervention (unrelated to mesh use)		5 years ; up to 8-year after index procedure
Percentage of patients who have had more than 1 surgical reintervention (unrelated to mesh use)		5 years ; up to 8-year after index procedure
Description of patients who have had more than 1 surgical reintervention (unrelated to mesh use)		5 years ; up to 8-year after index procedure
Patient impression of improvement of surgical reintervention assessed by the PGI-I-Reintervention	Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better". In case of reintervention, the patient will complete a PGI-I-Reintervention (same questionnaire as PGI-I) at 6 months after surgical reintervention.	6 months after surgical reintervention
Number of Adverse Device Effect		through study completion, at least 5 and up to 8 years
Percentage of Adverse Device Effect		through study completion, at least 5 and up to 8 years
Number of Restorelle mesh Device Deficiencies		through study completion, at least 5 and up to 8 years
Percentage of Restorelle mesh Device Deficiencies		through study completion, at least 5 and up to 8 years
Description of Restorelle mesh Device Deficiencies	The description of identified Restorelle mesh Device Deficiencies and categorized according to the association or not with Adverse Device Effect (ADE) or Serious ADE	through study completion, at least 5 and up to 8 years
Monitoring of postoperative pain related to Restorelle mesh use using the modified TOMUS/PREM questionnaire	Post-operative pain will be reported and evaluated by the patient using the modified TOMUS/PREM questionnaire through: Location and Intensity VAS; Pain duration: acute or chronic (more than 6 months); Treatment: types, drug name (if medication) and duration; Persistent pain, beyond 2 weeks, will be defined as havingpain intensity ≥ 40 (VAS) at any of locations (lower abdomen, vagina, lower back and back of legs/buttocks) or during any activity orpain medication use.	through study completion, at least 5 and up to 8 years
Changes of prolapse symptoms	The changes in the Pelvic Floor Disability Index (PFDI-20 questionnaire) total score and sub scores. Pelvic Floor Distress Inventory (PDFI-20) is comprised of 3 subscales for a total of 20 questions. Each question begins with a "yes" or "no" response. If "yes," the patient must indicate how much bowl, bladder, or pelvic symptoms have been bothering them in the past 3 months on a 4-point scale that ranges from "not at all" (0) to "quite a bit" (4). The scale scores are found individually by calculating the mean value of their corresponding questions and then multiplying by 25 to obtain a value that ranges from 0 to 100 (with higher scores indicating more distress/dysfunction). The sum of the 3 scales are added together to get the PFDI-20 summary score, which ranges from 0 to 300.	Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Prolapse symptoms - number	The number of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure	12 months ; 5 years
Prolapse symptoms - percentage	The percentage of patients rating "yes" at "vaginal bulge" determined by the PFDI-20/POPDI-6 and requiring additional treatment for POP since index procedure	12 months ; 5 years
Assessment of health related quality of life using the EQ-5D-5L questionnaire	The changes in QoL total score using EQ-5D-5L and their evolution. The General Health Outcome Status questionnaire (EQ-5D-5L) consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions which are divided into 5 levels of perceived problems: from level 1 indicating no problem to level 5 indicating extreme problems. The patient indicates her health state in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, from 'The best health you can imagine' to 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgment.	Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of health related quality of life using the PFIQ-7 questionnaire	The changes in QoL total score using the Pelvic Floor Impact Questionnaire (PFIQ-7) and their evolution. Pelvic Floor Impact Questionnaire (PFIQ-7) consists of 7 questions. The responses for each question range from "not at all" (0) to "quite a bit" (3). To get scale scores, the mean of each of the 3 scales is individually calculated, which ranges from 0-3, this number is then multiplied by 100 and then divided by 3. The scale scores are then added together to get the total PFIQ-7 score, which ranges from 0-300. A lower score means there is a lesser effect on quality of life.	Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the PISQ-IR questionnaire	Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire, IUGA revised (PISQ-IR): is composed of 20 items including the scales for arousal & orgasm, partner related, condition specific, global quality, condition impact and desire. The number of cases for each scale that can be scored. The mean and standard deviation are provided for each scale.	Pre-index procedure ; 2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Assessment of the sexual functioning by the changes in dyspareunia status of patients who are sexually active.		Pre-index procedure ; 12 months
Number of patients defining success via patient global impression of improvement (PGI-I) scale	Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".	2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients defining success via patient global impression of improvement (PGI-I) scale	Patient Global Impression of Improvement (PGI-I) is a 7-point scale that provides a single global measure of condition improvement from 'very much better' to 'very much worse' after treatment. The surgery is defined as successful if the patient felt "very much better" or "much better".	2 months ;12 months ; Every year (at least 5 and up to 8 years)
Number of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8).	Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".	2 months ; 12 months ; Every year (at least 5 and up to 8 years)
Percentage of patients satisfied after the index procedure as assessed by the Surgical Satisfaction Questionnaire (SSQ-8)	Surgical Satisfaction Questionnaire (SSQ-8): is a validated questionnaire used to measure patient satisfaction following a surgery to correct prolapse and/or incontinence. Answers of the SSQ questions consisted of a 5-point scale ranging from "very satisfied" to "very unsatisfied" or from "yes" to "never". Patients' satisfaction is defined if answers correspond with "very satisfied" and "satisfied" or "yes" and "may be".	2 months ; 12 months ; Every year (at least 5 and up to 8 years)

Collaborators and Investigators

• Sponsor: Coloplast A/S
• Collaborators: International Clinical Trials Association
• Investigators: Principal Investigator: Philippe Ferry, Dr, CH La Rochelle, France

Study record dates

Study Major Dates

• Study Start (Actual): November 21, 2023
• Primary Completion (Actual): November 6, 2024
• Study Completion (Actual): November 6, 2024

Study Registration Dates

• First Submitted: November 24, 2023
• First Submitted That Met QC Criteria: February 28, 2024
• First Posted (Actual): March 6, 2024

Study Record Updates

• Last Update Posted (Actual): January 28, 2026
• Last Update Submitted That Met QC Criteria: January 26, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Sacrocolpopexy; Pelvic organ prolapse; Apical prolapse; Transabdominal mesh; Sacrocervicopexy; Sacrohysteropexy
• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Prolapse; Pathological Conditions, Signs and Symptoms; Pelvic Organ Prolapse
• Other Study ID Numbers: IU022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is not a plan to make IPD available

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No